You can now read 10 articles each month for free on

The Boston Globe


Mass. Movers

Bank reaffirms ‘neutral’ rating on Idenix

Idenix aims to develop drugs to treat viral diseases.

Associated Press/File 2012

Idenix aims to develop drugs to treat viral diseases.

Continue reading below

Bank of America reaffirmed its “neutral” rating on shares of Cambridge-based Idenix Pharmaceuticals in a research note released Monday, according to Jags Report. The bank currently has a $7 price target, up from $6. Idenix announced a nonexclusive collaboration with Janssen Pharmaceuticals Inc. for “the clinical development of all-oral direct-acting antiviral HCV combination therapies” — in other words, drug combinations to treat infection with the hepatitis C virus.

You have reached the limit of 10 free articles a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than $1 a week